Literature DB >> 6448690

Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.

J P McGovren.   

Abstract

The magnitudes of the therapeutic and toxic responses observed when 7-con-O-methylnogarol (7-OMEN) was administered orally to mice inoculated ip or iv with P388 of L1210 leukemia were essentially equivalent to those seen after ip administration of the drug, indicating a significant degree of gastrointestinal absorption.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6448690

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  6 in total

1.  Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.

Authors:  E A Eisenhauer; K I Pritchard; D J Perrault; S Verma; J L Pater
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

Review 2.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Menogaril: a new anthracycline agent entering clinical trials.

Authors:  J P McGovren; K G Nelson; M Lassus; J C Cradock; J Plowman; J P Christopher
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Synergistic combination of menogarol and melphalan and other two drug combinations.

Authors:  B K Bhuyan; E G Adams; M Johnson; S L Crampton
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.

Authors:  M L Zanette; U Tirelli; R Sorio; D Zadro; F Figoli; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.

Authors:  G J Badiner; B C Moy; K S Smith; W G Tarpley; V E Groppi; B K Bhuyan
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.